As part of maintaining professional vigilance and regulatory compliance across pharmacy services, PCL would like to draw attention to several critical issues recently highlighted by the General Pharmaceutical Council (GPhC).
The UK is entering a new phase of innovation in how it regulates, assesses, and adopts new medicines—and it’s a development the global pharmaceutical and biopharmaceutical industry cannot afford to overlook.
The MHRA continue to scrutinise and take action against Pharmacies and Clinics who are promoting Prescription Only Medicines (POMs) to the public. However, this month’s advertising investigations bulletin also includes action against a journalist newspaper article.
In this blog I want to highlight some critical updates from the General Pharmaceutical Council (GPhC) that every pharmacy professional—whether you’re a pharmacist, technician, or pharmacy owner—should be aware of. These issues have prompted serious regulatory concerns and demand thoughtful consideration and action where appropriate.
Risk Assessments are a regulatory requirement in medicines wholesaling but have you considered that they could also be very useful in pharmacy practice?
